Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
time to tumor progression
Ron Epelbaum, MD
Principal Investigator
Israel: Israeli Health Ministry Pharmaceutical Administration
RonCurcuminPancreas.CTIL
NCT00192842
July 2004
September 2010
Name | Location |
---|